FY2025 EPS Forecast for Gilead Sciences Increased by Analyst

Key Points

• Cantor Fitzgerald increased its FY2025 EPS forecast for Gilead Sciences to $8.18, slightly up from a previous estimate of $8.15, while setting a target price of $135.00 for the stock.
• The consensus estimate for Gilead Sciences' full-year earnings stands at $7.95 per share, with other analysts also upgrading their ratings and price targets for the stock.
• Gilead Sciences recently announced a quarterly dividend of $0.79 per share, translating to an annualized dividend yield of 2.7% and a payout ratio of 62.95%.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for shares of Gilead Sciences in a note issued to investors on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will earn $8.18 per share for the year, up from their previous forecast of $8.15. Cantor Fitzgerald currently has a "Overweight" rating and a $135.00 target price on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share. Cantor Fitzgerald also issued estimates for Gilead Sciences' FY2026 earnings at $8.75 EPS.

Several other equities analysts have also commented on GILD. Weiss Ratings restated a "buy (b)" rating on shares of Gilead Sciences in a report on Wednesday. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and raised their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $118.08.

Gilead Sciences Trading Down 1.3%

Shares of GILD stock opened at $116.74 on Friday. Gilead Sciences has a 1-year low of $84.17 and a 1-year high of $121.83. The firm has a market cap of $144.85 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The company has a 50-day moving average of $114.57 and a two-hundred day moving average of $110.19. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period last year, the company earned $2.01 EPS. The company's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GILD. Rothschild Investment LLC raised its position in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company's stock worth $503,000 after acquiring an additional 84 shares in the last quarter. Ignite Planners LLC increased its stake in Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company's stock valued at $880,000 after purchasing an additional 86 shares during the last quarter. Archer Investment Corp raised its holdings in Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company's stock worth $807,000 after purchasing an additional 87 shares in the last quarter. Binnacle Investments Inc lifted its position in shares of Gilead Sciences by 14.3% during the 2nd quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company's stock worth $78,000 after buying an additional 88 shares during the last quarter. Finally, EPG Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 2.0% in the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company's stock valued at $513,000 after buying an additional 89 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider owned 113,193 shares of the company's stock, valued at $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares of the company's stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $9,402,130 over the last 90 days. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.